Citations

Clear

3314 citation(s) found for "Do, Alexander".

Utility of Carpal Tunnel Release and Ulnar Decompression in CMT1A and HNPP
Chompoopong, Pitcha , Niu, Zhiyv , Shouman, Kamal , Madigan, Nicolas N. , Sandroni, Paola , Berini, Sarah E. , Brault, Jeffrey S. , Boon, Andrea J. , Laughlin, Ruple S. , Thorland, Erik C., Mandrekar, Jay , Thorland, Erik, Klein, Christopher J , Chompoopong, Pitcha , Niu, Zhiyv , Shouman, Kamal , Shin, Alexander Y. , Klein, Christopher J.

Mayo Clinic

Muscle & Nerve | July 27, 2022 | Volume: 66 | Issue: 4 | Pages: 479-486

10.1002/mus.27687 | PMID 35894586 Get It

Abstract Introduction/Aims Carpal and cubital tunnel syndrome (CTS, CuTS) are common among patients with hereditary neuropathy with liability to pressure‐palsies (HNPP) and Charcot–Marie‐Tooth type 1A (CMT1A) and may impact quality of life. We aimed to evaluate the utility of nerve decompression surgeries in these patients. Methods Medical records were reviewed for patients with PMP22 mutations confirmed in Mayo Clinic laboratories from January 1999 to December 2020, who had CTS and CuTS and underwent surgical decompression. Results CTS occurred in 53.3% of HNPP and 11.5% of CMT1A, while CuTS was present in 43.3% of HNPP and 5.8% of CMT1A patients. CTS decompression occurred in 10‐HNPP and 5‐CMT1A patients, and CuTS decompression with/without transposition was performed in 5‐HNPP and 1‐CMT1A patients. In HNPP, electrodiagnostic studies identified median neuropathy at the wrist in 9/10 patients and ultrasound showed focal enlargements at the carpal and cubital tunnels. In CMT1A, median and ulnar sensory responses were all absent, and the nerves were diffusely enlarged. After CTS surgery, pain, sensory loss, and strength improved in 4/5 CMT1A, and 6/10 HNPP patients. Of clinical, electrophysiologic and ultrasound findings, only activity‐provoked features significantly correlated with CTS surgical benefit in HNPP patients (odds ratio = 117.0:95% confidence interval, 1.94 > 999.99, p = 0.01). One CMT1A and one HNPP patient improved with CuTS surgery while 2 HNPP patients worsened. Discussion CTS symptom improvement post‐surgery can be seen in CMT1A and (less frequent) in HNPP patients. CuTS surgery commonly worsened course in HNPP. Activity‐provoked symptoms in HNPP best informed benefits from CTS surgery.
The effect of surgical revascularization on the mechanical properties of cryopreserved bone allograft in a porcine tibia model
Visser, Noortje J., Rezaie, Elisa S., Ducharme, Alexandra M. , Bishop, Allen T. , Visser, Noortje, Rezaie, Elisa, Ducharme, Alexandra, Bishop, Allen T , Ducharme, Alexandra , Shin, Alexander Y.

Mayo Clinic

Journal of Orthopaedic Research | July 26, 2022 | Volume: 41 | Issue: 4 | Pages: 815-822

10.1002/jor.25422 | PMID 35880353 Get It

AbstractCryopreserved bone allografts(CBA) are susceptible to infection, nonunion, and late stress fracture. Although surgical revascularization by intramedullary implantation of an arteriovenous bundle (AV bundle) generates a neoangiogenic blood supply, there is potential for vascular ingrowth‐mediated bone resorption to weaken the graft. For this reason, we have evaluated changes in CBA mechanical properties of structural tibial allografts with and without surgically induced angiogenesis. Cryopreserved tibia bone allografts were transplanted to reconstruct a 3.5 cm segmental tibial defect in 16 Yucatan mini pigs. Surgical revascularization was performed in half by implantation of a cranial tibial AV bundle, (revascularization group). A control group of identical size had a ligated AV bundle implanted, (ligated group). At 20 weeks micro‐computed tomography (CT) measured bone mineral density (BMD) as well as bone union. Reference point indentation (RPI) compared cortex material properties, and axial compression determined the allotransplant compressive modulus. Seven of eight tibiae in the angiogenesis group were healed at both junction points at 20 weeks. Only four of eight tibiae healed in the ligated control group. There was no significant difference between the revascularization and ligated control groups in BMD and axial compression test. Similarly, RPI parameters were statistically equal. In paired comparisons with contralateral tibias, however, some RPI values were significantly worse in the ligated control group tibiae. This study demonstrates no adverse effect of surgical angiogenesis on cryopreserved structural bone allograft biomechanical properties in a large animal orthotopic segmental tibial defect model. These data suggest the potential value of surgical angiogenesis in clinical limb‐sparing reconstructive surgery.
Prognosis is worse with elevated cardiac troponin in nonacute coronary syndrome compared with acute coronary syndrome
Horiuchi, Yu , Patel, Mitul , Mueller, Christian, Neath, Sean‐Xavier , Christenson, Robert H. , Morgenthaler, Nils G., McCord, James , Nowak, Richard M. , Vilke, Gary M. , Daniels, Lori B. , Apple, Fred S. , Cannon, Chad , Nagurney, John T., Schreiber, Donald , Diercks, Deborah B. , Headden, Gary , Limkakeng, Alexander T. , Wu, Alan H.B. , Ebmeyer, Stefan , Jaffe, Allan S. , Maisel, Alan S. , Daniels, Lori B , Wettersten, Nicholas , Hollander, Judd E. , deFilippi, Christopher R. , Hogan, Christopher , Anand, Inder S. , Jaffe, Allan S. , Peacock, William Frank

Mayo Clinic

Coronary Artery Disease | July 26, 2022 | Volume: 33 | Issue: 5 | Pages: 376-384

10.1097/mca.0000000000001135 | PMID 35880560 Get It

Background Cardiac troponin (cTn) can be elevated in many patients presenting to the emergency department (ED) with chest pain but without a diagnosis of acute coronary syndrome (ACS). We compared the prognostic significance of cTn in these different populations. Methods We retrospectively analyzed the CHOPIN study, which enrolled patients who presented to the ED with chest pain. Patients were grouped as ACS, non-ACS cardiovascular disease, noncardiac chest pain and chest pain not otherwise specified (NOS). We examined the prognostic ability of cTnI for the clinical endpoints of mortality and major adverse cardiovascular event (MACE; a composite of acute myocardial infarction, unstable angina, revascularization, reinfarction, and congestive heart failure and stroke) at 180-day follow-up. Results Among 1982 patients analyzed, 14% had ACS, 21% had non-ACS cardiovascular disease, 31% had a noncardiac diagnosis and 34% had chest pain NOS. cTnI elevation above the 99th percentile was observed in 52, 18, 6 and 7% in these groups, respectively. cTnI elevation was associated with mortality and MACE, and their relationships were more prominent in noncardiac diagnosis and chest pain NOS than in ACS and non-ACS cardiovascular diagnoses for mortality, and in non-ACS patients than in ACS patients for MACE (hazard ratio for doubling of cTnI 1.85, 2.05, 8.26 and 4.14, respectively; P for interaction 0.011 for mortality; 1.04, 1.23, 1.54 and 1.42, respectively; P for interaction <0.001 for MACE). Conclusion In patients presenting to the ED with chest pain, cTnI elevation was associated with a worse prognosis in non-ACS patients than in ACS patients.
COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies
Gil‐Vila, Albert , Ravichandran, Naveen , Selva-O’Callaghan, Albert , Sen, Parikshit , Nune, Arvind , Gaur, Prithvi Sanjeevkumar , Joshi, Mrudula , Agarwal, Vishwesh , Kardeş, Sinan , Kim, Minchul , Day, Jessica , Milchert, Marcin , Salim, Babur , Velikova, Tsvetelina , Gracia‐Ramos, Abraham Edgar , Parodis, Ioannis , Nikiphorou, Elena , Tan, Ai Lyn , Chatterjee, Tulika , Ziadé, Nelly , Kuwana, Masataka , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Singh, Yogesh Preet , Needham, Merrilee , Loarce‐Martos, Jesus , Ordóñez, Andrea Bran , Gupta, Latika , Lilleker, James B , Joshi, Mrudula , Agarwal, Vishwesh , Kardes, Sinan , Kim, Minchul , Day, Jessica , Makol, Ashima , Milchert, Marcin , Gheita, Tamer , Salim, Babur , Velikova, Tsvetelina , Gracia-Ramos, Abraham Edgar , Parodis, Ioannis , Nikiphorou, Elena , Tan, Ai Lyn , Chatterjee, Tulika , Cavagna, Lorenzo , Saavedra, Miguel A , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Knitza, Johannes , Kuwana, Masataka , Distler, Oliver , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Selva O'Callaghan, Albert , Nune, Arvind , Naveen, R , Sen, Parikshit , Singh, Yogesh Preet , Gonzalez, Raquel Arànega, Makol, Ashima , Gheita, Tamer A. , Shinjo, Samuel Katsuyuki , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study

Mayo Clinic

Muscle & Nerve | July 23, 2022 | Volume: 66 | Issue: 4 | Pages: 426-437

10.1002/mus.27681 | PMID 35869701 Get It

AbstractIntroduction/AimsIn this study we investigated COVID‐19 vaccination–related adverse events (ADEs) 7 days postvaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs).MethodsSeven‐day vaccine ADEs were collected in an international patient self‐reported e‐survey. Descriptive statistics were obtained and multivariable regression was performed.ResultsTen thousand nine hundred respondents were analyzed (1227 IIM cases, 4640 SAID cases, and 5033 healthy controls [HCs]; median age, 42 [interquartile range, 30‐455] years; 74% female; 45% Caucasian; 69% completely vaccinated). Major ADEs were reported by 76.3% of the IIM patients and 4.6% reported major ADEs. Patients with active IIMs reported more frequent major (odds ratio [OR], 2.7; interquartile range [IQR], 1.04‐7.3) and minor (OR, 1.5; IQR, 1.1‐2.2) ADEs than patients with inactive IIMs. Rashes were more frequent in IIMs (OR, 2.3; IQR, 1.2‐4.2) than HCs. ADEs were not impacted by steroid dose, although hydroxychloroquine and intravenous/subcutaneous immunoglobulins were associated with a higher risk of minor ADEs (OR, 1.9; IQR, 1.1‐3.3; and OR, 2.2; IQR, 1.1‐4.3, respectively). Overall, ADEs were less frequent in inclusion‐body myositis (IBM) and BNT162b2 (Pfizer) vaccine recipients.DiscussionSeven‐day postvaccination ADEs were comparable in patients with IIMs, SAIDs, and HCs, except for a higher risk of rash in IIMs. Patients with dermatomyositis with active disease may be at higher risk, and IBM patients may be at lower risk of specific ADEs. Overall, the benefit of preventing severe COVID‐19 through vaccination likely outweighs the risk of vaccine‐related ADEs. Our results may inform future guidelines regarding COVID‐19 vaccination in patients with SAIDs, specifically in those with IIMs. Studies to evaluate long‐term outcomes and disease flares are needed to shed more light on developing future COVID‐19 vaccination guidelines.
Development of a Prediction Model for COVID‐19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry
Izadi, Zara , Aguirre, Alfredo , Hyrich, Kimme L , Gossec, Laure , Carmona, Loreto , Lawson‐Tovey, Saskia , Kearsley‐Fleet, Lianne , Schaefer, Martin, Seet, Andrea M. , Schmajuk, Gabriela , Jacobsohn, Lindsay, Rush, Stephanie, Sparks, Jeffrey A. , Hsu, Tiffany , Gilbert, Emily, Valenzuela-Almada, Maria O , Ugarte‐Gil, Manuel F. , Ribeiro, Sandra Lúcia Euzébio , Marinho, Adriana de Oliveira , Valadares, Lílian David de Azevedo , Hasseli, Rebecca , Richter, Jutta , Schmeiser, Tim , Torres, Alvaro Andres Reyes , Alle, Gelsomina , Saurit, Verónica , Zanetti, Anna , Carrara, Greta , Labreuche, Julien , Barnetche, Thomas , Hérasse, Muriel, Plassart, Samira, Santos, María José , Machado, Pedro , Sirotich, Emily , Hausmann, Jonathan S. , Sufka, Paul , Grainger, Rebecca , Bhana, Suleman , Costello, Wendy, Wallace, Zachary S. , Registry, Global Rheumatology Alliance, Schäfer, Martin , Gianfrancesco, Milena A , Aguirre, Alfredo , Lawson-Tovey, Saskia , Kearsley-Fleet, Lianne , Schaefer, Martin , Schmajuk, Gabriela , Katz, Patricia , Al-Emadi, Samar , Sparks, Jeffrey A , Wise, Leanna M , Duarte-García, Alí , Ribeiro, Sandra Lúcia Euzébio , Pfeil, Alexander , Santos, Maria José , Robinson, Philip C , Machado, Pedro M , Hausmann, Jonathan S , Grainger, Rebecca , Yazdany, Jinoos , Ugarte-Gil, Manuel F , Carmona, Loreto , Gossec, Laure , Hasseli, Rebecca , Hyrich, Kimme L , Sirotich, Emily , Hsu, Tiffany Y-T , Mateus, Elsa F , Strangfeld, Anja , Mateus, Elsa F , Katz, Patricia , Patel, Naomi J , Wise, Leanna , Duarte‐García, Alí , Di Giuseppe, Daniela , Isnardi, Carolina A , Saurit, Verónica , Khaldi-Plassart, Samira , Rodrigues, Ana Maria , Robinson, Philip C. , Liew, Jean W. , Yazdany, Jinoos , Registry, Global Rheumatology Alliance

Mayo Clinic

ACR Open Rheumatology | July 23, 2022 | Volume: 4 | Issue: 10 | Pages: 872-882

10.1002/acr2.11481 | PMID 35869686 Get It

ObjectiveSome patients with rheumatic diseases might be at higher risk for coronavirus disease 2019 (COVID‐19) acute respiratory distress syndrome (ARDS). We aimed to develop a prediction model for COVID‐19 ARDS in this population and to create a simple risk score calculator for use in clinical settings.MethodsData were derived from the COVID‐19 Global Rheumatology Alliance Registry from March 24, 2020, to May 12, 2021. Seven machine learning classifiers were trained on ARDS outcomes using 83 variables obtained at COVID‐19 diagnosis. Predictive performance was assessed in a US test set and was validated in patients from four countries with independent registries using area under the curve (AUC), accuracy, sensitivity, and specificity. A simple risk score calculator was developed using a regression model incorporating the most influential predictors from the best performing classifier.ResultsThe study included 8633 patients from 74 countries, of whom 523 (6%) had ARDS. Gradient boosting had the highest mean AUC (0.78; 95% confidence interval [CI]: 0.67‐0.88) and was considered the top performing classifier. Ten predictors were identified as key risk factors and were included in a regression model. The regression model that predicted ARDS with 71% (95% CI: 61%‐83%) sensitivity in the test set, and with sensitivities ranging from 61% to 80% in countries with independent registries, was used to develop the risk score calculator.ConclusionWe were able to predict ARDS with good sensitivity using information readily available at COVID‐19 diagnosis. The proposed risk score calculator has the potential to guide risk stratification for treatments, such as monoclonal antibodies, that have potential to reduce COVID‐19 disease progression.
Phase II Study of Enzalutamide for Patients With Androgen Receptor–Positive Salivary Gland Cancers (Alliance A091404)
Ho, Alan L. , Foster, Nathan R. , Zoroufy, Alexander , Campbell, Jordan D., Price, Katharine A., Adkins, Douglas R. , Bowles, Daniel W. , Kang, Hyunseok , Sherman, Eric J. , Morton, Roscoe F., Nadeem, Zaineb , Katabi, Nora , Münster, Pamela N. , Price, Katharine, Adkins, Douglas , Bowles, Daniel W , Kang, Hyunseok , Burtness, Barbara , Sherman, Eric , Morris, Luc G T , Munster, Pamela , Ho, Alan L , Worden, Francis P. , Burtness, Barbara , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | July 22, 2022 | Volume: 40 | Issue: 36 | Pages: 4240-4249

10.1200/jco.22.00229 | PMID 35867947 Get It

PURPOSE The androgen receptor (AR) is expressed (+) in a subset of salivary gland cancers (SGCs). This phase II trial evaluated the efficacy of the antiandrogen enzalutamide in AR+ SGC. METHODS Patients with locally advanced/unresectable or metastatic AR+ SGCs were enrolled. Enzalutamide (160 mg) was given orally once daily. The primary end point was the best overall response rate per RECIST v1.1 within eight cycles. Confirmed responses in ≥ 5 of 41 patients would be considered promising. Secondary end points were progression-free survival, overall survival, and safety. RESULTS Forty-six patients were enrolled; 30 (65.2%) received prior systemic therapy, including 13 (28.3%) with AR-targeted drugs. Of seven (15.2%) partial responses (PRs), only two (4.3%) were confirmed per protocol and counted toward the primary end point. Twenty-four patients (52.2%) had stable disease; 15 (32.6%) had progression of disease as best response. Twenty-six patients (56.5%) experienced tumor regression in target lesions; 18 (39.1%) had partial response/stable disease ≥ 6 months. Tumor regressions were observed in female patients (5 of 6 [83.3%]) and those who received prior AR– (6 of 13 [46.2%]) or human epidermal growth factor receptor 2–targeted therapies (5 of 8 [62.5%]). Three patients remained on treatment at data cutoff (duration, 32.2-49.8 months). The median progression-free survival was 5.6 months (95% CI, 3.7 to 7.5); the median overall survival was 17.0 months (95% CI, 11.8 to 30.0). The most common adverse events were fatigue, hypertension, hot flashes, and weight loss. Total and free testosterone levels increased by a mean of 61.2% and 48.8%, respectively, after enzalutamide. CONCLUSION Enzalutamide demonstrated limited activity in AR+ SGC, failing to meet protocol-defined success in part because of a lack of response durability. Strategies to enhance the efficacy of antiandrogen therapy are needed.
Echo-Doppler and strain assessment of filling pressures in adults with congenitally corrected transposition and systemic right ventricles
Jain, C. Charles , Egbe, Alexander C. , Oh, Jae K. , Connolly, Heidi M. , Miranda, William R. , Charles Jain, C

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | July 22, 2022 | Volume: 24 | Issue: 4 | Pages: 454-462

10.1093/ehjci/jeac115 | PMID 35866302 Get It

Abstract Aims Systolic dysfunction of the systemic right ventricle (sRV) is common in adults with transposition of the great arteries and sRV. In acquired disease, diastology analysis for assessment of filling pressures (FP) is paramount in patient care. Methods and results Retrospective analysis of 47 adults with sRV without prior systemic tricuspid valve surgery undergoing catheterization and echocardiography within 7 days (median −2 [−1, −3]) from January 2000 to February 2021 at our institution. Median age was 48 (31, 55) years, and 16 (34.0%) patients were female. FPs were normal in 21 patients (44.7%). Left atrial size was enlarged in most patients (83.0%) with mean indexed value 58.3 ± 23.4 mL/m2. Tissue Doppler e′ was not significantly different between those with high FPs vs. normal (medial 0.07 ± 0.03 vs. 0.08 ± 0.03 m/s, P = 0.63; lateral 0.08 ± 0.04 vs. 0.08 ± 0.04 m/s, P = 0.88). E velocity and subpulmonic mitral regurgitant velocity were higher in those with high FPs (0.9 ± 0.3 vs. 0.6 ± 0.2 m/s, P = 0.005; 3.8 ± 1.1 vs. 2.8 ± 0.9 m/s, P = 0.004). Left atrial reservoir strain, sRV global longitudinal strain, and subpulmonic left ventricular strain were worse in those with high FP (18.0 ± 7.6 vs. 27.9 ± 10.2%, P = 0.0009; −13.0 ± 4.4 vs. −17.9 ± 5.0%, P = 0.002; −16.8 ± 5.7 vs. −23.0 ± 3.8%, P = 0.001). Conclusion Despite the complex anatomy, FPs can be assessed non-invasively in adults with sRV without prior systemic tricuspid valve surgery. The current guideline algorithm for diastolic dysfunction in acquired heart disease has limited applicability in this population. Given the limitations of Doppler in this heterogeneous population, strain analysis can be a helpful adjunct for estimation of FPs.
Cost‐Effectiveness of Arthroscopic Partial Meniscectomy and Physical Therapy for Degenerative Meniscal Tear
Williams, Emma E. , Leifer, Valia P., Collins, Jamie E. , Neogi, Tuhina , Suter, Lisa G., Levy, Bruce A. , Farid, Alexander, Safran‐Norton, Clare E., Collins, Jamie E , Neogi, Tuhina , Losina, Elena , Williams, Emma E , Katz, Jeffrey N. , Paltiel, A. David , Losina, Elena

Mayo Clinic

ACR Open Rheumatology | July 22, 2022 | Volume: 4 | Issue: 10 | Pages: 853-862

10.1002/acr2.11480 | PMID 35866194 Get It

ObjectiveWe examined the cost‐effectiveness of treatment strategies for concomitant meniscal tear and knee osteoarthritis (OA) involving arthroscopic partial meniscectomy surgery and physical therapy (PT).MethodsWe used the Osteoarthritis Policy Model, a validated Monte Carlo microsimulation, to compare three strategies, 1) PT‐only, 2) immediate surgery, and 3) PT + optional surgery, for participants whose pain persists following initial PT. We modeled a cohort with baseline meniscal tear, OA, and demographics from the Meniscal Tear in Osteoarthritis Research (MeTeOR) trial of arthroscopic partial meniscectomy versus PT. We estimated risks and costs of arthroscopic partial meniscectomy complications and accounted for heightened OA progression post surgery using published data. We estimated surgery use rates and treatment efficacies using MeTeOR data. We considered a 5‐year time horizon, discounted costs, and quality‐adjusted life‐years (QALYs) 3% per year and conducted sensitivity analyses. We report incremental cost‐effectiveness ratios.ResultsRelative to PT‐only, PT + optional surgery added 0.0651 QALY and $2,010 over 5 years (incremental cost‐effectiveness ratio = $30,900 per QALY). Relative to PT + optional surgery, immediate surgery added 0.0065 QALY and $3080 (incremental cost‐effectiveness ratio = $473,800 per QALY). Incremental cost‐effectiveness ratios were sensitive to optional surgery efficacy in the PT + optional surgery strategy. In the probabilistic sensitivity analysis, PT + optional surgery was cost‐effective in 51% of simulations at willingness‐to‐pay thresholds of both $50,000 per QALY and $100,000 per QALY.ConclusionFirst‐line arthroscopic partial meniscectomy has a prohibitively high incremental cost‐effectiveness ratio. Under base case assumptions, second‐line arthroscopic partial meniscectomy offered to participants with persistent pain following initial PT is cost‐effective at willingness‐to‐pay thresholds between $31,000 and $473,000 per QALY. Our analyses suggest that arthroscopic partial meniscectomy can be a high‐value treatment option for patients with meniscal tear and OA when performed following an initial PT course and should remain a covered treatment option.
Analysis of 101 Mechanical Failures in Distal Femur Fractures Treated with 3 Generations of Precontoured Locking Plates
Collinge, Cory A. , Reeb, Alexander Francis, Rodriguez-Buitrago, Andres , Archdeacon, Michael T. , Beltran, Michael J. , Jeray, Kyle J. , Miller, Anna N. , Sems, S.A. , Shah, Nihar S. , Fogel, Nathaniel , Tibbo, Meagan E. , Tibbo, Meagan, Gardner, Michael J. , Crist, Brett D.

Mayo Clinic

Journal of Orthopaedic Trauma | July 21, 2022 | Volume: 37 | Issue: 1 | Pages: 8-13

10.1097/bot.0000000000002460 | PMID 35862769 Get It

Objectives: To evaluate mechanical treatment failure in a large patient cohort sustaining a distal femur fracture treated with a distal femoral locking plate (DFLP). Design: This retrospective case–control series evaluated mechanical treatment failures of DFLPs. Setting: The study was conducted at 8 Level I trauma centers from 2010 to 2017. Patients and Participants: One hundred one patients sustaining OTA/AO 33-A and C distal femur fractures were treated with DFLPs that experienced mechanical failure. Intervention: The intervention included the treatment of a distal femur fracture with a DFLP, affected by mechanical failure (implant failure by loosening or breakage). Main Outcome Measure: The main outcome measures included injury and DFLP details; modes and timing of failure were studied. Results: One hundred forty-six nonunions were found overall (13.4%) including 101 mechanical failures (9.3%). Failures occurred in different manners, locations, and times depending on the DFLPs. For example, 33 of 101 stainless steel (SS) plates (33%) failed by bending or breaking in the working length, whereas no Ti plates failed here ( P < 0.05). Eleven of 12 failures with titanium-Less Invasive Stabilization System (92%) occurred by lost shaft fixation, mostly by the loosening of unicortical screws (91%). Sixteen of 44 variable –angled–LCP failures (36%) occurred at the distal plate–screw junction, whereas only 5 of 61 other DFLPs (8%) failed this way ( P < 0.05). Distal failures occurred on average at 23.7 weeks compared with others that occurred at 38.4 weeks ( P < 0.05). Variable –angled–LCP distal screw–plate junction failures occurred earlier (mean 21.4 weeks). Conclusion: Nonunion and mechanical failure occurred in 14% and 9% of patients, respectively, in this large series of distal femur fracture treated with a DFLP. The mode, location, presence of a prosthesis, and timing of failure varied depending on the characteristics of DFLP. This information should be used to optimize implant usage and design to prolong the period of stable fixation before potential implant failures occur in patients with a prolonged time to union. Level of Evidence: Economic Level IV. See Instructions for Authors for a complete description of levels of evidence.
TSH and FT4 Reference Intervals in Pregnancy: A Systematic Review and Individual Participant Data Meta-Analysis
Osinga, J. , Derakhshan, Arash , Richards, C. Sue , Ashoor, Ghalia, Männistö, Tuija , Chen, Liangmiao , Bliddal, Sofie , Lu, Xuemian , Taylor, Peter , Tao, Fangbiao , Ghafoor, Farkhanda, Veltri, Flora, Chatzi, Lida , Vaidya, Bijay , Broeren, Maarten A.C., Shields, Beverley M. , Itoh, Sachiko, Mosso, Lorena , Popova, Polina , Anopova, Anna D. , Kishi, Reiko , Kianpour, Maryam, López‐Bermejo, Abel , Oken, Emily , Pirzada, Amna, Vafeiadi, Marina , Suvanto, Eila, Yoshinaga, Jun , Boucai, Laura , Grineva, Elena , Pearce, Elizabeth N. , Alexander, Erik K. , Pop, Victor J.M. , Nelson, Scott M. , Walsh, John P. , Chaker, Layal , D’Alton, Mary E. , Korevaar, Tim I.M. , Osinga, Joris A J , Bliddal, Sofie , Taylor, Peter N , Brown, Suzanne J , López-Bermejo, Abel , Oken, Emily , Boucai, Laura , Feldt-Rasmussen, Ulla , Alexander, Erik K , Nelson, Scott McGill , Walsh, John P , Richards, C. Sue , Mosso, Lorena , Pearce, Elizabeth N , Maraka, Spyridoula , Vrijkotte, Tanja G. M. , Poppe, Kris Gustave , Aminorroaya, Ashraf , Kianpour, Maryam , Bramer, Wichor Matthijs , Huang, Kun , Bassols, Judit , Peeters, Robin P. , Nicolaides, Kypros H.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 21, 2022 | Volume: 107 | Issue: 10 | Pages: 2925-2933

10.1210/clinem/dgac425 | PMID 35861700 Get It

Abstract Context Interpretation of thyroid function tests during pregnancy is limited by the generalizability of reference intervals between cohorts due to inconsistent methodology. Objective (1) To provide an overview of published reference intervals for thyrotropin (TSH) and free thyroxine (FT4) in pregnancy, (2) to assess the consequences of common methodological between-study differences by combining raw data from different cohorts. Methods (1) Ovid MEDLINE, EMBASE, and Web of Science were searched until December 12, 2021. Studies were assessed in duplicate. (2) The individual participant data (IPD) meta-analysis was performed in participating cohorts in the Consortium on Thyroid and Pregnancy. Results (1) Large between-study methodological differences were identified, 11 of 102 included studies were in accordance with current guidelines; (2) 22 cohorts involving 63 198 participants were included in the meta-analysis. Not excluding thyroid peroxidase antibody–positive participants led to a rise in the upper limits of TSH in all cohorts, especially in the first (mean +17.4%; range +1.6 to +30.3%) and second trimester (mean +9.8%; range +0.6 to +32.3%). The use of the 95th percentile led to considerable changes in upper limits, varying from –10.8% to –21.8% for TSH and –1.2% to –13.2% for FT4. All other additional exclusion criteria changed reference interval cut-offs by a maximum of 3.5%. Applying these findings to the 102 studies included in the systematic review, 48 studies could be used in a clinical setting. Conclusion We provide an overview of clinically relevant reference intervals for TSH and FT4 in pregnancy. The results of the meta-analysis indicate that future studies can adopt a simplified study setup without additional exclusion criteria.